Systems BiologybioRxivPreprint
Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in In Vitro, In Vivo and Ex Vivo Models of Pulmonary Fibrosis
Farida Ahangari, Christine Becker, Daniel G. Foster…·Gregory Paul Downey
This study identifies saracatinib as a potential anti-fibrotic drug effective in multiple models of pulmonary fibrosis, showing equal or superior efficacy compared to existing treatments.
1 citation